News

A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.

The oral S1P receptor modulator has promise to break new ground for disease modification.

Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.

The investigative JAK inhibitor therapy provided significantly better skin clearance and resolved pain at 8 weeks with 2 different doses.

Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.

Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.

Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.

COVID-19 patients receiving at least 2 antibiotics were at a higher CDI risk.

New research over 2 decades shows patients with opioid use disorder are often prescribed opioid analgesic prior to OUD diagnosis, although rates have decreased in recent years.

A majority of studies reported a worsening of disease activity post-delivery.

Dr. Jennifer Payne discusses how the events of the last year has impacted her patients and what needs to happen to improve mental health care in the future.

The 2021 annual report finds that Los Angeles remains the most polluted US city, while negative impacts of climate change and COVID-19 are both linked to increased pollution rates.

The odds of suicidal behavior was 49% lower for OUD patients receiving substance use disorder treatment.

New data show female veterans receive poorer secondary prevention care in treating premature and extremely premature atherosclerotic cardiovascular disease, compared to male veterans.

An expert writes on the value of shared knowledge into the intricacies of allergic risks.

Direct-acting antivirals have been a major milestone in the treatment of hepatitis C virus, new data show they also work in nearly all children, without serious adverse events.

Data also suggests the nonionic block polymer surfactant may be harmful for children <16 years of age.

Recent data finds children treated for allergies with ≥14 consecutive days of corticosteroids experienced greater incidence rates than those not treated with a corticosteroid.

Larger and longer clinical trials are needed to further test the treatment as a suitable option to treat depression.

Experts share insights on how they have utilized Prescription Monitoring Programs to combat the opioid crisis and improve the safety of prescribed opioids.

Experts share approaches to normalize conversations about naloxone with patients, as well as share important considerations for maximizing naloxone education.

ABX464 is being tested for numerous indications, including ulcerative colitis.

The monoclonal antibody was linked to significant improvements in endoscopic nasal polyp and nasal obstruction symptom visual analogue scale scores.

Dr. Anthony Fauci believes the Johnson & Johnson vaccine pause will soon end.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

A new study finds patients with atrial fibrillation or venous thromboembolism were at higher risk of increased bleeding and hospitalization when treated with combination DOAC and aspirin.

The approval expands the current sublingual tablet treatment indications to include children with a ragweed pollen allergy.

A trio of experts from the Cleveland Clinic join Dr. Rizzo for a talk on lung transplant trends and challenges in the US.